Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 18 art units • 22 examiners • 0 of 22 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Trustees of Boston University has 22 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed across 22 distinct examiners and 17 distinct art units, indicating that each matter may require a tailored prosecution assessment. The art-unit distribution also suggests that technical positioning should be reviewed alongside examiner assignment.
AKANBI, ISIAKA O is the busiest identified examiner, with 1 pending matter. No examiner cluster dominates the profile, so portfolio management is better served by matter-specific prior-art review, response planning, and deadline control than by a single shared examiner strategy.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 2 (9%) |
| §102 only | 2 (9%) |
| §112 only | 1 (5%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 5 (23%) |
| Multi-statute (no §101) | 10 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| NUR, ABDULLAHI | 1 | 88.2% | +6.1% |
| STOCK JR, GORDON J | 1 | 81.6% | +17.4% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| SUMLAR, JOURNEY F | 1 | 69.2% | +11.5% |
| MEDWAY, SCOTT J | 1 | 66.6% | +23.0% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19037115 | STIMULATED RAMAN PHOTOTHERMAL MICROSCOPE WITH OPTICAL PARAMETRIC AMPLIFIER SOURCE | NUR, ABDULLAHI | — |
| 18923191 | FLUORESCENCE-CODED MID-INFRARED PHOTOTHERMAL MICROSCOPE | STOCK JR, GORDON J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16771510 | Inducible Cell Receptors for Cell-Based Therapeutics | CHEONG, CHEOM-GIL | 153d overdue |
| 17793287 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | 74d overdue |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | GROSS, CHRISTOPHER M | 53d overdue |
| 18215420 | INFUSION PUMP AND SYSTEM FOR PREVENTING MISCHANNELING OF MULTIPLLE MEDICAMENTS | VU, QUYNH-NHU HOANG | 15d |
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | LEITH, NANCY J | 35d |
| 18115335 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | GREENE, CAROLYN LEE | 76d |
| 19080346 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | LI, RUIXIANG | — |
| 18605472 | DIAGNOSIS AND PROGNOSIS OF RICHTER'S SYNDROME | SWITZER, JULIET CAROLINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | LEITH, NANCY J | 35d |
| 19171111 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF | RICCI, CRAIG D | — |
| 19080346 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | LI, RUIXIANG | — |
| 18923191 | FLUORESCENCE-CODED MID-INFRARED PHOTOTHERMAL MICROSCOPE | STOCK JR, GORDON J | — |
| 18605472 | DIAGNOSIS AND PROGNOSIS OF RICHTER'S SYNDROME | SWITZER, JULIET CAROLINE | — |
| 18578671 | OPTICAL SCAN MULTIPLIER AND USES THEREOF | SUMLAR, JOURNEY F | — |
| 18488359 | DRUG-COATED ENDOVASCULAR DEVICES | MEDWAY, SCOTT J | — |
| 18553474 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 2877 | 2 |
| 3783 | 2 |
| 1628 | 2 |
| 1684 | 2 |
| 1636 | 1 |
| 1611 | 1 |
| 1674 | 1 |
| 1672 | 1 |
| 1682 | 1 |
| 2872 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | LEITH, NANCY J | 1636 | §102§103 | Final Rejection | 35d | Pending | Apr 09, 2025 |
| 19171111 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF | RICCI, CRAIG D | 1611 | §102 | Final Rejection | — | Pending | Apr 04, 2025 |
| 19080346 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | LI, RUIXIANG | 1674 | §102§112 | Final Rejection | — | Pending | Mar 14, 2025 |
| 19037115 | STIMULATED RAMAN PHOTOTHERMAL MICROSCOPE WITH OPTICAL PARAMETRIC AMPLIFIER SOURCE | NUR, ABDULLAHI | 2877 | DP | Non-Final OA | — | Pending | Jan 25, 2025 |
| 18923191 | FLUORESCENCE-CODED MID-INFRARED PHOTOTHERMAL MICROSCOPE | STOCK JR, GORDON J | 2877 | §102DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18827183 | SELF-REPLICATING RNA AND USES THEREOF | CHESTNUT, BARRY A | 1672 | §102§103DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18605472 | DIAGNOSIS AND PROGNOSIS OF RICHTER'S SYNDROME | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18578671 | OPTICAL SCAN MULTIPLIER AND USES THEREOF | SUMLAR, JOURNEY F | 2872 | §103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18488359 | DRUG-COATED ENDOVASCULAR DEVICES | MEDWAY, SCOTT J | 3783 | §103§112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18553474 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | BARSKY, JARED | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18275731 | SELECTIVE ROCK2 INHIBITION FOR TREATMENT OF EDEMA AND ASSOCIATED CONDITIONS | SZNAIDMAN, MARCOS L | 1628 | §102§103DP | Final Rejection | — | Pending | Aug 03, 2023 |
| 18215420 | INFUSION PUMP AND SYSTEM FOR PREVENTING MISCHANNELING OF MULTIPLLE MEDICAMENTS | VU, QUYNH-NHU HOANG | 3783 | §103§112 | Non-Final OA | 15d | Pending | Jun 28, 2023 |
| 18206947 | METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS | HUI, SAN MING R | 1627 | §103§112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18308899 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | 1d overdue | Pending | Apr 28, 2023 |
| 18115335 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | GREENE, CAROLYN LEE | 1681 | §103§112 | Non-Final OA | 76d | Pending | Feb 28, 2023 |
| 18016497 | VIRAL DETECTION SYSTEMS AND USES THEREOF | BLUMEL, BENJAMIN P | 1671 | §102§112 | Non-Final OA | — | Pending | Jan 17, 2023 |
| 17793287 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Final Rejection | 74d overdue | Pending | Jul 15, 2022 |
| 17695073 | STRUCTURED SUBSTRATES FOR OPTICAL SURFACE PROFILING | FLINDERS, JEREMY C | 1684 | §102Other | Non-Final OA | 7d | Pending | Mar 15, 2022 |
| 17600957 | METHODS OF PREDICTING AND PREVENTING CANCER IN PATIENTS HAVING PREMALIGNANT LESIONS | ESSEX, LAURA ANN | 1675 | §112 | Non-Final OA | — | Pending | Oct 01, 2021 |
| 17376138 | SYNTHETIC HEPARIN MIMETICS AND USES THEREOF | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Jul 14, 2021 |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | GROSS, CHRISTOPHER M | 1684 | §103§112 | Non-Final OA | 53d overdue | Pending | Feb 22, 2021 |
| 16771510 | Inducible Cell Receptors for Cell-Based Therapeutics | CHEONG, CHEOM-GIL | 1645 | §103§112 | Non-Final OA | 153d overdue | Pending | Jun 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrustees of Boston University has 22 pending office actions as of October 2026, spread across 18 art units and 22 examiners.
Nancy J Leith has the most, with 1 of Trustees of Boston University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
